Takeda Pharmaceutical Co.'s Actos diabetes drug may be kept on the market with new warnings, the European Medicines Agency said after reviewing research showing the drug carried a slightly increased risk of bladder cancer. The benefits of pioglitazone, the active ingredient in Actos and other diabetes treatments, outweigh its risks in a limited group of patients with type 2 diabetes, the London ...